Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Cosentyx® (secukinumab) – New indication
October 31, 2023 - Novartis announced the FDA approval of Cosentyx (secukinumab), for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS).
